P1.01-74 A Retrospective Study Evaluating Clinical Predictors of Duration of Response to Immune Checkpoint Inhibitors in Advanced NSCLC
Younis Ibrahim(Wayne State University), Hirva Mamdani(Wayne State University), Hassan Mouzaihem(Wayne State University), K. Nathan Sankar(Cedars-Sinai Medical Center), Abdo Haddad(Providence Park Hospital), S. Kim(The Barbara Ann Karmanos Cancer Institute)
Cited by 0
Related Papers
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|116
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
|Frontiers in Cell and Developmental Biology|2020|80
Blood-based tumor biomarkers in lung cancer for detection and treatment
|Translational Lung Cancer Research|2017|75